A Clinical Study on Drug Resistance in CML(Chronic Myeloid Leukemia)
Not Applicable
- Conditions
- Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismHealth Condition 2: D70-D77- Other disorders of blood and blood-forming organsHealth Condition 3: D72- Other disorders of white blood cellsHealth Condition 4: D728- Other specified disorders of whiteblood cells
- Registration Number
- CTRI/2024/08/072505
- Lead Sponsor
- Indian Council Of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male or female aged = 18 years
Diagnosis of CML: Any patient who is planned for TKI or already taking TKI
Exclusion Criteria
Another active malignancy at the time of diagnosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantitative and Qualitative analysis of PBMC in different phase of CML patients using Molecular Techniques. <br/ ><br>Identification of disease relevant phospho-signature in TKI therapy sensitive and resistant CML patients. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: The non-responders patients will have 3 data points at 0, 3, and 18 months while the sensitive patients will have two data points at 0 and 3 months.
- Secondary Outcome Measures
Name Time Method Interrogative signaling pathway analysis utilizing newly developed phospho-PRM assay. <br/ ><br>Dose- dependent analysis and validation of newly developed assay in large cohort of CML patient samples. <br/ ><br>Timepoint: The non-responders patients will have 3 data points at 0, 3, and 18 months while the sensitive patients will have two data points at 0 and 3 months.